Company Overview - CANbridge Pharmaceuticals aims to be a global biopharmaceutical company with a foundation in China, delivering life-changing therapies to patients[7] - The company has raised a total capital of $357 million since 2015 through multiple funding rounds and an IPO[12, 13] - CANbridge has a commercialization team of over 40 experienced professionals in Greater China[30] Pipeline and Products - CANbridge has 2 marketed rare disease products and 4 late-stage clinical programs[19] - The company anticipates 3 registration filings/approvals in the next 12 months for LIVMARLI in MPS II ALGS in Mainland China, ALGS in Hong Kong, and ALGS in Taiwan[19] - Hunterase has entered into 109 cities' commercial insurance program ("Huiminbao") as of June 30, 2023, covering a population of 586 million in China, with 72% of Hunterase treated patients covered by commercial insurance[32, 63] - Livmarli achieved $751 million in net product sales in the first full fiscal year of its U S launch[69] Market and Financials - The global rare disease drug market was $259 billion in 2020 and is projected to reach $383 billion by 2030[40] - China's contribution to the global rare disease market is currently less than 1%[40] - Orphan drugs achieved combined sales of $173 billion globally in 2022[43] - The company identified 739 MPS II patients[61] - The company's revenue increased by RMB 84 million year-over-year due to increased sales of Hunterase and Livmarli[163]
CANbridge Pharmaceuticals (01228) Earnings Call Presentation